Published in final edited form as:

Mol Neurobiol. 2014 August ; 50(1): 186–196. doi:10.1007/s12035-014-8634-8.

Amyloid β -peptide 1-42 modulates the proliferation of mouse neural stem cells: Up-regulation of fucosyltransferase-IX and Notch signaling

Yutaka Itokazu and Robert K Yu*

Institute of Molecular Medicine and Genetics and Institute of Neuroscience, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, and Charlie Norwood VA Medical Center, Augusta, GA 30904

Abstract

Amyloid β -peptides (A β s) aggregate to form amyloid plaques, also known as senile plaques, which are a major pathological hallmark of Alzheimer's disease (AD). A β s are reported to possess proliferation effects on neural stem cells (NSCs); however, this effect remains controversial. Thus, clarification of their physiological function is an important topic. We have systematically evaluated the effects of several putative bioactive A β s (A β 1-40, A β 1-42, and A β 25-35) on NSC proliferation. Treatment of NSCs with A β 1-42 significantly increased the number of those cells (149 ± 10 %). This was not observed with A β 1-40 which did not have any effects on the proliferative property of NSC. A β 25-35, on the other hand, exhibited inhibitory effects on cellular proliferation. Since cell surface glycoconjugates, such as glycolipids, glycoproteins, and proteoglycans, are known to be important for maintaining cell fate determination, including cellular proliferation, in NSCs and they undergo dramatic changes during differentiation, we examined the effect of A β s on a number of key glycoconjugate metabolizing enzymes. Significantly, we found for the first time that A β 1-42 altered the expression of several key glycosyltransferases and glycosidases, including fucosyltransferase-IX (FUT9), sialyltransferase-III (ST-III), glucosylceramide ceramidase (GLCC), and sialidase (Neu4). FUT9 is a key enzyme for the synthesis of the Lewis x carbohydrate epitope, which is known to be expressed in stem cells. A β 1-42 also stimulated the Notch1 intracellular domain (NICD) by up-regulation of the expression of Musashi-1 and the paired box protein, Pax6. Thus, A β 1-42 up-regulates NSC proliferation by modulating the expression of several glycogenes involved in Notch signaling.

Keywords

Alzheimer's disease; amyloid β -peptide; glycosyltransferase; glycogene; neural stem cell; cell proliferation

*Corresponding Author: Dr. Robert K. Yu, Institute of Molecular Medicine and Genetics and Institute of Neuroscience, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912. ryu@gru.edu.

Conflict of Interest

The authors declare no conflict of interest.

Introduction

Alzheimer's disease (AD) is one of the most common forms of dementia with clinical symptoms that include deficits in memory, judgment, thinking, and behavior. These symptoms usually develop slowly and become worse over time, interfere with daily tasks, and ultimately lead to death. It is well accepted that deposition of aggregated amyloid β -protein ($A\beta$) to form amyloid plaques, also known as senile plaques, together with associated reactive astrocytosis and dystrophic neuritis, represent major pathological hallmarks of AD [3]. There are two dominant forms of $A\beta$ s, $A\beta$ 1-40 and $A\beta$ 1-42. Both have a high tendency to assemble initially into the soluble form, and later to form insoluble aggregated fibrils as extracellular amyloid plaques in the AD brain. Intermediate soluble oligomers of $A\beta$ s, rather than the aggregated $A\beta$ s, are increasingly recognized as having cellular toxicity in Alzheimer's disease [4,5].

Neural stem cells (NSCs) are undifferentiated neural cells characterized by their high proliferative potential and the capacity for self-renewal with retention of multipotency, i.e., generating brain-forming cells such as neurons, astrocytes, and oligodendrocytes. Our previous *in vitro* study showed that soluble $A\beta$ 1-42 dramatically increased the number of NSCs, but soluble $A\beta$ 1-40 did not [6]. Both the aggregated forms of $A\beta$ 1-40 and $A\beta$ 1-42 promoted the proliferation of NSCs, but soluble and aggregated $A\beta$ 25-35 showed inhibitory effects. As well as pathological conditions, it has been also reported that $A\beta$ s are produced by cultured cells during normal cellular metabolism [7,8]. Because $A\beta$ 1-40 and $A\beta$ 1-42 are present in the brain and cerebrospinal fluid of normal individuals, it suggests that these peptides are likely physiologically active in normal life [9]. Despite extensive efforts for studying $A\beta$ s for their cytotoxic effects in AD, the normal biological functions and positive effects of $A\beta$ s have remained elusive.

Gangliosides are sialic acid-containing glycosphingolipids (GSLs) expressed primarily in the outer leaflet of the plasma membrane of all vertebrate cells and are particularly abundant in the nervous system [10,11]. The expression of neural gangliosides changes dramatically during cellular differentiation and brain development. For instance, in rodent brains a shift from the synthesis of simple gangliosides, such as GM3 and GD3, to the synthesis of the more complex gangliosides in the a- and b-series during brain development has been well documented [12,13]. A2B5 monoclonal antibody was reported [14] in 1979, and it recognizes c-series gangliosides including GQ1c, GT1c and GT3 [15,16] and to some extent sulfatide [17]. The c-series gangliosides are abundant in embryonic mammalian brains, but not in adult brain [18,19]. During development, A2B5 antigens are expressed in glial precursor cells [20]. Significant changes in ganglioside patterns in AD brains have been reported; major gangliosides such as GM1, GD1a, GD1b and GT1b are all decreased in AD patients brain and b-series gangliosides such as GD1b and GT1b are preferentially affected [21–25]. Additionally, in frontal and parietal cortex simple gangliosides, including GM2, GM3, GM4 and GD3, are elevated. These findings suggest that abnormal ganglioside metabolism coincides with the affected brain region of neurodegeneration in AD patients. In AD mouse brain, it was reported that GT1a, GD1a and GQ1b are slightly decreased and there are increases of minor gangliosides such as GM2, GM3 and GD3 in the cerebral cortex [26]. Most interestingly, we have reported there is an increase of cholinergic neuronal

marker gangliosides such as GT1ac and GQ1ba in AD mouse brain [27]. *In vitro* experiments also revealed that hippocampal neuronal cultures treated with A β 25–35 showed enhanced metabolism of lipids such as gangliosides and phospholipids [28]. In addition, exposure of rat cultured cortical neurons to A β 25–35 induced a substantial increase of the intracellular GD3 levels [29]. Those reports suggest that A β s can modulate ganglioside metabolism in neural cells and prompted us to hypothesize that A β s could alter glycogene expression in NSCs to account for the ganglioside changes.

Stage-specific embryonic antigen-1 (SSEA-1/Lewis X/CD15) is a well-known carbohydrate antigenic epitope of undifferentiated cells and has been recognized as an NSC marker [30]. The 3-fucosyl-*N*-acetylglucosamine or Lewis X carbohydrate structure is defined as [Gal β 1-4(Fuc α 1-3)GlcNAc β]-. Lewis X carbohydrate epitope is synthesized by transferring a fucose residue from GDP-fucose to *N*-acetylglucosamine (GlcNAc) by the action of α 1,3-fucosyltransferase-IX (FUT9) [31]. Recently, we showed that FUT9 knockdown in mouse NSCs impaired Musashi-1 expression and NSC proliferation [32], suggesting that NSC proliferation can be modulated by FUT9 and the Notch signaling pathway.

In this study, we investigated the possibility that proliferation of NSCs stimulated by A β 1-42 is associated with altered glycogene expression in the NSCs. Here we demonstrated that A β 1-42 significantly activated the expression of several enzymes, including fucosyltransferase-IX (FUT9), sialyltransferase-III (ST-III), glucosylceramide ceramidase (GLCC), and sialidase (Neu4). A β 1-42 also markedly activated several NSC markers, such as paired box protein (Pax6), Musashi-1 and Notch1 intracellular domain (NICD). Our present study thus provides a novel mechanism for the up-regulation of Musashi-1 expression with an increase of FUT9 to account for the proliferative effect of A β 1-42.

Materials and Methods

Materials

A β 1-40, A β 1-42 and A β 25-35 were purchased from Bachem Americas (Torrance, CA). Freshly prepared soluble A β s were used for the experiments. Antibodies used were as follows: anti-Notch-1 (mouse) (BD Biosciences, San Jose, CA), and anti-actin (rabbit) (Sigma-Aldrich, St. Louis, MO)

Neural stem cell culture

Mouse NSCs were prepared from embryonic brains in the form of neurospheres, which were floating clonal aggregates formed by NSCs *in vitro* [33]. In brief, single-cell suspensions prepared from the striata of embryonic mouse brains [embryonic day (E)-14.5] by mechanical trituration were cultured in Neurobasal A medium (Life Technologies, Carlsbad, CA) supplemented with B27 (Life Technologies) and 20 ng/ml of basic fibroblast growth factor (Peprotech, Rocky Hill, NJ) and 20 ng/ml of epidermal growth factor (Peprotech). Neurospheres formed after 1 week were collected for further passages and analyses. The use of animals for this study was approved by the Institutional Animal Care and Use Committees at Georgia Regents University and the VA Medical Center, Augusta, GA.

WST-8 assay

The number of NSCs cultured in the presence or absence of A β s was estimated by the WST-8 assay using a Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). The dissociated NSCs from neurospheres were plated at a density of 1×10^4 cells per well onto 96-well plates that had been coated with poly-L-ornithine (Sigma-Aldrich) and fibronectin (Sigma-Aldrich). On the next day, A β s dissolved in media were added to each well. The total volume of the culture media was 100 μ l/well. After 3 days of culture, 10 μ l of WST-8 solution was added to each well. After incubating for 3 hours in a CO₂ incubator, the spectrophotometric absorbance of WST-8-formazan produced by the dehydrogenase activity in the living neural cells was measured at the wavelength of 450 nm using a Benchmark Plus Microplate Spectrophotometer (Bio-Rad Laboratories, Hercules, CA). The spectrophotometric absorbance measured by this assay was highly correlated with the number of living NSCs.

Reverse transcription-polymerase chain reaction

Total RNA samples were isolated from cultured NSCs using the Trizol reagent (Life Technologies). cDNAs were synthesized based on the total RNAs as templates using MultiScribeTM Reverse Transcriptase (Applied Bioscience). PCR was performed using ReadyMixTM REDTaq[®] (Sigma-Aldrich) with the following settings: 94°C for 5 min; 26–32 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s; and 72°C for 5 min. The primer sets used for PCR analysis are shown in Table 1. PCR products were analyzed by agarose gel electrophoresis using 1.5% agarose gels containing SYBR SafeTM DNA Gel stain (Life Technologies). The bands were quantified using the NIH ImageJ 1.46r image processing program (rsb.info.nih.gov) to reflect the original mRNA levels. Densitometric data were normalized against G3PDH (glycerol-3-phosphate dehydrogenase), a ubiquitously expressed enzyme catalyzing an essential step of glycolysis, mRNA. The normalized value from control (vehicle) is defined as 1.0.

Western blotting

NSCs were washed with PBS, lysed in RIPA buffer containing 50 mM Tris-HCl, 150 mM NaCl, 5 mM NaF, 1 mM Na₃VO₄, 1% NP-40, 0.5% sodium deoxycholate, and 1% SDS, pH 7.5, supplemented with a complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN), and then centrifuged at $12,000 \times g$ and 4°C for 10 min. Supernatants (cell lysates) were collected and the protein concentrations were measured using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific Inc., Rockford IL). Proteins were separated by SDS-PAGE (8 % gel) under reducing conditions and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were probed with primary antibodies followed by appropriate secondary antibodies conjugated with horseradish peroxidase (HRP, BD Biosciences). Signals were visualized with Western Lightning Western blot chemiluminescence reagent (Perkin Elmer Life and Analytical Sciences, Boston, MA). The bands were quantified using the NIH ImageJ. Densitometric values were normalized by setting the NICD/Actin protein ratio for control (vehicle) in each treatment. The normalized value from control (vehicle) is defined as 1.0.

Statistical evaluation

Data are expressed as means $\pm$ standard deviation (SD) from three to eight independent experiments. Statistical significance was determined using unpaired two-tailed *t*-test and $p < 0.05$ was regarded as significant.

Results

Increased number of NSCs by treatment with A β 1-42

To assess the effect of the two major A β peptides (Fig. 1A) on NSCs, isolated NSCs were plated, A β 1-40 or A β 1-42 was added the following day, and living cells were measured 3 days after treatments. We measured the number of NSCs by the WST-8 assay; the spectrophotometric absorbance measured by this assay is known to be highly correlated with the number of living NSCs [34,35]. The relative absorbance of the WST-8 assay revealed the percentage of absorbance vs. vehicle treatment. We confirmed that treatment of NSCs with 10 μ M of A β 1-42 significantly increased the number of cells (149 %). This proliferative effect was observed only with A β 1-42 but not with A β 1-40 (10 μ M). A β 25-35, on the other hand, exhibited inhibitory effects on cellular proliferation (data not shown). These results are consistent with our previous study [6] and that by others [36–39] that showed A β 1-42 promoted NSC proliferation. In the previous study [6], TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) assay, an indicator of cell death accompanied by DNA fragmentation, revealed that there were no significant TUNEL-positive cells in the intact cells and NSCs treated with the soluble forms of A β s. This result was also consistent with our previous report that showed the expression of active caspase 3 was not different in intact cells and NSCs treated with the soluble form of A β 1-40 [40]. These treatments of A β 1-40 and A β 1-42 were not toxic for NSCs in this culture system. Taken together, it suggests that the increase of cell number with soluble A β 1-42 was likely caused by cell proliferation rather than by protection the cells from undergoing apoptosis.

Alteration of glycosyltransferase and glycosidase gene expressions by A β s

Cell surface glycoconjugates are known to be important for maintaining stem cells, and their expression is dramatically altered during differentiation [10,11]. The expression of gangliosides changes remarkably during neuronal differentiation and brain development [12,13]. The expression of gangliosides is regulated primarily by glycosyltransferases and glycosidases (Fig. 2). For this reason, we analyzed the gene expression patterns of several key glycosyltransferases and glycosidases in NSCs treated with A β 1-40 or A β 1-42. Most of the glycosyltransferases involved in ganglioside synthesis, such as ceramide glucosyltransferase (GlcT), galactosyltransferase (GalT-1), sialyltransferase-I (ST-I), ST-II (GD3-synthase), N-acetylgalactosaminyltransferase (GalNAcT, GM2/GD2-synthase), and GalT-II, showed no significant difference after treatment by the two A β s. On the other hand, the expression of ST-IV, ST-V and β -N-acetylhexaminidase β -subunit (HEX β) increased by treatment with the two A β s (Fig.3). We found that treatment with A β 1-42 greatly increased the expression of certain glycosyltransferases, specifically, FUT9, sialyltransferase-III (ST-III), and glycosidases including glucocerebrosidase (GLCC), mitochondrial sialidase (Neu4) (Fig. 3). Treatment with either A β 1-40 or 1-42 decreased the expression of ST-VII, β -N-acetylhexaminidase α -subunit (HEX α), and GM2 activator protein (GM2A). Our results

thus show that A β treatment had a profound effect on the expression pattern of specific glycogenes in NSCs. FUT9 is not involved in ganglioside metabolism, but is a key enzyme for the synthesis of Lewis X-carrying N-glycans, which has been utilized as an NSC marker. In our previous study, FUT9 was shown to be expressed in NSCs and down-regulated in differentiated cells [41]. Increasing the expression of this key enzyme, FUT9, by A β 1-42 is expected to affect NSC proliferation.

Expression of specific NSC markers

Next, we performed RT-PCR experiments and evaluated if A β s affected the differentiation state of NSCs. Fig. 4A shows that A β treatments did not change the expression of the mRNA of a neuronal marker (MAP2), glial marker (GFAP), and an NSC marker, nestin, in NSCs. These data suggest that A β treatment did not affect the differentiation stages of NSCs. However, we found that the protein expression of the Notch1 intracellular domain (NICD) was up-regulated after A β 1-42 treatment (Fig. 4B). Since we found FUT9 was also up-regulated after A β 1-42 treatment, we postulated that the regulator of FUT9 should also be affected. Pax6 is known to promote proliferation of neural progenitor cells and neurogenesis [42]. Since it was reported that Pax6 controls the expression of FUT9 in the embryonic brain of rodents [43], we next analyzed PAX6 mRNA expression. This is consistent with the fact that A β 1-42 increased Pax6 expression as revealed by our RT-PCR experiment. Recently, we reported that FUT9 regulates the proliferation of NSCs via modulation of the expression of Musashi-1 [32]. Musashi-1 plays a crucial role in maintaining the undifferentiated state of NSCs via activation of the Notch signaling pathway [44,45]. Numb protein was known to bind Notch-1 protein and inhibit the activation of the Notch signaling pathway. On the other hand, Musashi-1 protein binds to Numb mRNA and inhibits its translation, and Musashi-1 enhances Notch signaling by inhibiting Numb translation [45]. Therefore we performed an RT-PCR experiment and examined Musashi-1 expression after A β treatment. Intriguingly, A β 1-42 increased Musashi-1 gene expression in NSCs (Fig. 4B). Our data thus are consistent with the following sequence of events: A β 1-42 stimulated Notch signaling, which is followed by increased expression of Pax6, FUT9 and Musashi-1, and regulation of NSC proliferation.

Discussion

The present study provides the first evidence that soluble A β 1-42 promotes NSC proliferation by modulation of FUT9 and Notch signaling. We and others have previously reported that soluble A β 1-42 stimulated NSC proliferation. Soluble A β 1-40, on the other hand, has no effect on NSC proliferation. The mechanism of NSC proliferation stimulated by A β 1-42, however, is not well understood. For this reason, we investigated the potential mechanisms of A β 1-42-stimulated NSC proliferation. Two major forms of A β s, A β 1-40 and A β 1-42, are known (Fig. 1A). During normal metabolism of amyloid protein (APP), A β 1-40 is abundantly produced [46]; however, A β 1-42 is the major peptidic constituent of amyloid plaques. *In vitro*, freshly dissolved A β 1-42 generates more stable dimer formation than does A β 1-40 [47]. A β 1-42 has less configurational entropy and is found to confer higher rigidity on the C-terminus, which may explain its higher amyloidogenic ability [48]. Yang and Teplow [49] reported that the addition of two terminal hydrophobic residues, isoleucine and

alanine, on A β 1-42, significantly increases the contact between the C-terminus and the central hydrophobic clusters. This additional hydrophobic interaction significantly stabilizes the β -sheet structure of A β 1-42 as compared with that for A β 1-40. These structural characteristics of A β 1-42 may affect its interaction with the cell membrane and consequently its activity for promotion of NSC proliferation, as revealed by our observation.

With respect to A β 25-35, this peptide is considered as having the functional and responsible domain for the neurotoxic properties of A β s [50]. Both A β 1-42 and A β 25-35 are known to be incorporated into phospholipid membranes. In the model lipid membrane system, the incorporated A β 1-42 tends to destabilize the lipid bilayer, whereas A β 25-35 inserted into the hydrophobic acyl-chain region of the phospholipid membrane to enhance membrane stability [51,52]. Treatment of A β 25-35 (50 μ M) induces rapid cell lysis of red blood cells, whereas exposure of red blood cells to the same concentration of A β 1-42 induces no significant lysis [53]. It has also been reported that A β 25-35 is more neurotoxic and causes more membrane protein oxidation than does A β 1-42 [54]. The oxidation of the methionine residue in the peptide is believed to proceed through a free radical intermediate [55]. Substitution of methionine 35 in A β 25-35 inhibits the aggregation, apoptotic effects, and neurotoxicity of the peptide [56,57]. Intriguingly, A β 25-36 which has one additional amino residue on A β 25-35 is no longer toxic to cultured neurons [54]. These observations on the property of A β 25-35 are consistent with our finding that treatment of NSCs with A β 25-35 decreased the number of NSCs.

Cell surface glycoconjugates, including glycoproteins, glycolipids, and proteoglycans, are known to play important functional roles in NSC maintenance. These carbohydrate-containing antigens serve as excellent cell surface biomarkers at various stages of cellular differentiation. A2B5 antibody recognizes c-series gangliosides, including GT3, GT1c and GQ1c [15]. These c-series gangliosides are abundant in fish brains and embryonic mammalian brains [58,59]. In embryonic brain and spinal cord, A2B5 antigens are expressed in glial precursor cells [20]. We found that the expression of ST-III, which is a key enzyme for the synthesis of c-series gangliosides, increased after A β 1-42 treatment. This result suggests that the up-regulated ST-III should promote the increased synthesis of c-series gangliosides, which are expressed in embryonic brain. It is intriguing to suggest that A β 1-42 treatment might promote proliferation as evidenced by the increased expression of neural progenitor cell (NPC) markers as observed in the current study.

Mouse Neu4 sialidase is predominantly expressed in brain [60]. In Neuro2A cells, the level of Neu4 gene expression decreases during retinoic acid-induced neuronal differentiation [61]. Trinngali *et al.* reported that overexpression of the Neu4 gene enhances an undifferentiated stem cell-like phenotype and cell proliferation in human neuroblastoma cells [62]. We have also confirmed that proliferating mouse NSCs, NPCs, and glial progenitor cells highly express Neu4 mRNA (data not shown) in culture. On the other hand, Neu4 expression decreases during neuronal and glial differentiation (data not shown). Thus, our data that A β 1-42 stimulated Neu4 expression is consistent with those observations and may contribute to NSC proliferation and inhibit differentiation.

We also found changes in gene expression in NSCs treated with A β 1-40 unaccompanied by a proliferative effect. These altered glycogenes are not considered to regulate cell proliferation *per se*. In AD patient and AD mouse brains, it has been reported that there are significant changes in the ganglioside expression pattern. GM1, GD1a, GD1b and GT1b are all decreased in AD patient brain, and GT1a, GD1a and GQ1b are slightly decreased in AD mouse brain [26,21–25]. Additionally, simple gangliosides such as GM2, GM3 and GD3 are elevated. Altered glycogene expression can be considered to contribute to the observed changes in ganglioside composition. For example, decreased complex gangliosides and increased simple gangliosides in AD brain might be related to the up-regulation of HEX β and desialylations from complex gangliosides. Increased expressions of ST-IV and ST-V should contribute to increased levels of complex gangliosides, such as GT1a, GD1a and GQ1b that are decreased in AD brain. However, evaluation of the precise functions of the altered glycogenes *in vivo* would require further studies.

A monoclonal antibody (mAb) against SSEA-1/CD15 was first established by immunization with F9 embryonic carcinoma cells [63]; subsequently the antigenic oligosaccharide structure that contained the Lewis X structure was established as Gal β 1-4(Fuc α 1-3)GlcNAc β -[64]. In a previous study [41], we found that the mRNA expression level of FUT9 was down-regulated in cells that were differentiated from NSCs. Recently we reported that Lewis X-carrying N-glycans, which account for 20% of the total N-glycans in NSCs, disappeared during differentiation [32]. By knocking down a FUT9 with a short interfering RNA (RNAi), we reported that the Lewis X-carrying N-glycans were actively involved in proliferating NSCs via modulation of the expression level of Musashi-1 [32]. In the current study, we found that A β 1-42 up-regulated the expression of Pax6, which is known to control FUT9 expression. The increased Pax6 and FUT9 stimulated by A β 1-42 resulted in up-regulation of Musashi-1 expression. Furthermore, A β 1-42 enhanced the amount of NICD with increased NSC proliferation. Taken together, our findings provide insights to the functional role of A β 1-42 as an active modulator of glycogenes and Notch signaling for promotion of NSC self-renewal and proliferation.

Acknowledgments

This work was supported in part by a VA Merit Review Award (1 IO1BX001388 to RKY) and NIH grants (RO1 NS26994 and RO1 NS11853 to RKY).

Abbreviations

AD	Alzheimer's disease
Aβ	amyloid β -protein
FUT9	fucosyltransferase-IX
NSC	neural stem cell
TUNEL	terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling.
	Gangliosides are abbreviated using the nomenclatural rules of IUPAC-IUB [1] and according to Svennerholm [2].

References

1. The nomenclature of lipids. Recommendations. IUPAC-IUB Commission on Biochemical Nomenclature (1977). *Lipids*. 1976; 12 (6):455–468.
2. Svennerholm L. Chromatographic Separation of Human Brain Gangliosides. *J Neurochem*. 1963; 10:613–623. [PubMed: 14066623]
3. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. *Science*. 1997; 275 (5300): 630–631. [PubMed: 9019820]
4. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat Neurosci*. 2012; 15(3):349–357. nn.3028 [pii]. 10.1038/nn.3028 [PubMed: 22286176]
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*. 2002; 297(5580):353–356. 297/5580/353 [pii]. 10.1126/science.1072994 [PubMed: 12130773]
6. Itokazu Y, Kato-Negishi M, Nakatani Y, Ariga T, Yu RK. Effects of Amyloid beta-Peptides and Gangliosides on Mouse Neural Stem Cells. *Neurochem Res*. 2013;10.1007/s11064-013-1108-y
7. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. *Nature*. 1992; 359 (6393):322–325.10.1038/359322a0 [PubMed: 1383826]
8. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. *Nature*. 1992; 359 (6393):325–327.10.1038/359325a0 [PubMed: 1406936]
9. Shoji M. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. *Front Biosci*. 2002; 7:d997–1006. [PubMed: 11897565]
10. Yu RK, Nakatani Y, Yanagisawa M. The role of glycosphingolipid metabolism in the developing brain. *J Lipid Res*. 2009; 50(Suppl):S440–445. R800028-JLR200 [pii]. 10.1194/jlr.R800028-JLR200 [PubMed: 18845618]
11. Yu RK, Tsai YT, Ariga T. Functional roles of gangliosides in neurodevelopment: an overview of recent advances. *Neurochem Res*. 2012; 37 (6):1230–1244.10.1007/s11064-012-0744-y [PubMed: 22410735]
12. Ngamukote S, Yanagisawa M, Ariga T, Ando S, Yu RK. Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. *J Neurochem*. 2007; 103 (6): 2327–2341. JNC4910 [pii]. 10.1111/j.1471-4159.2007.04910.x [PubMed: 17883393]
13. Yu RK, Macala LJ, Taki T, Weinfield HM, Yu FS. Developmental changes in ganglioside composition and synthesis in embryonic rat brain. *J Neurochem*. 1988; 50 (6):1825–1829. [PubMed: 3131485]
14. Eisenbarth GS, Walsh FS, Nirenberg M. Monoclonal antibody to a plasma membrane antigen of neurons. *Proc Natl Acad Sci U S A*. 1979; 76 (10):4913–4917. [PubMed: 388422]
15. Kasai N, Yu RK. The monoclonal antibody A2B5 is specific to ganglioside GQ1c. *Brain Res*. 1983; 277(1):155–158. 0006-8993(83)90918-6 [pii]. [PubMed: 6640289]
16. Saito M, Kitamura H, Sugiyama K. The specificity of monoclonal antibody A2B5 to c-series gangliosides. *J Neurochem*. 2001; 78 (1):64–74. [PubMed: 11432974]
17. Majocha RE, Jungalwala FB, Rodenrys A, Marotta CA. Monoclonal antibody to embryonic CNS antigen A2B5 provides evidence for the involvement of membrane components at sites of Alzheimer degeneration and detects sulfatides as well as gangliosides. *J Neurochem*. 1989; 53 (3): 953–961. [PubMed: 2668446]
18. Freischutz B, Saito M, Rahmann H, Yu RK. Activities of five different sialyltransferases in fish and rat brains. *J Neurochem*. 1994; 62 (5):1965–1973. [PubMed: 8158143]
19. Rosner H, Greis C, Henke-Fahle S. Developmental expression in embryonic rat and chicken brain of a polysialoganglioside-antigen reacting with the monoclonal antibody Q 211. *Brain Res*. 1988; 470 (2):161–171. [PubMed: 3064875]
20. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. *Nature*. 1983; 303 (5916):390–396. [PubMed: 6304520]

21. Crino PB, Ullman MD, Vogt BA, Bird ED, Volicer L. Brain gangliosides in dementia of the Alzheimer type. *Arch Neurol*. 1989; 46 (4):398–401. [PubMed: 2705899]
22. Kalanj S, Kracun I, Rosner H, Cosovic C. Regional distribution of brain gangliosides in Alzheimer's disease. *Neurol Croat*. 1991; 40 (4):269–281. [PubMed: 1751644]
23. Kracun I, Kalanj S, Cosovic C, Talan-Hranilovic J. Brain gangliosides in Alzheimer's disease. *J Hirnforsch*. 1990; 31 (6):789–793. [PubMed: 2092064]
24. Kracun I, Kalanj S, Talan-Hranilovic J, Cosovic C. Cortical distribution of gangliosides in Alzheimer's disease. *Neurochem Int*. 1992; 20 (3):433–438. [PubMed: 1304338]
25. Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). *J Neurochem*. 1994; 62 (3):1039–1047. [PubMed: 8113790]
26. Barrier L, Ingrand S, Damjanac M, Rioux Bilan A, Hugon J, Page G. Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease. *Neurobiol Aging*. 2007; 28 (12):1863–1872. S0197-4580(06)00297-1 [pii]. 10.1016/j.neurobiolaging.2006.08.002 [PubMed: 17007963]
27. Ariga T, Yanagisawa M, Wakade C, Ando S, Buccafusco JJ, McDonald MP, Yu RK. Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1alpha antigens in the brain. *ASN Neuro*. 2010; 2 (4):e00044.10.1042/AN20100021 [PubMed: 20930939]
28. Cazzaniga E, Bulbarelli A, Cassetti A, Lonati E, Re F, Palestini P, Mutoh T, Masserini M. Beta-amyloid (25–35) enhances lipid metabolism and protein ubiquitination in cultured neurons. *J Neurosci Res*. 2007; 85 (10):2253–2261.10.1002/jnr.21354 [PubMed: 17510978]
29. Copani A, Melchiorri D, Caricasole A, Martini F, Sale P, Carnevale R, Gradini R, Sortino MA, Lenti L, De Maria R, Nicoletti F. Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. *J Neurosci*. 2002; 22(10):3963–3968. 20026378 22/10/3963 [pii]. [PubMed: 12019315]
30. Yanagisawa M, Yu RK. The expression and functions of glycoconjugates in neural stem cells. *Glycobiology*. 2007; 17 (7):57R–74R. cwm018 [pii]. 10.1093/glycob/cwm018
31. Kudo T, Ikehara Y, Togayachi A, Kaneko M, Hiraga T, Sasaki K, Narimatsu H. Expression cloning and characterization of a novel murine alpha1, 3-fucosyltransferase, mFuc-TIX, that synthesizes the Lewis x (CD15) epitope in brain and kidney. *J Biol Chem*. 1998; 273 (41):26729–26738. [PubMed: 9756916]
32. Yagi H, Saito T, Yanagisawa M, Yu RK, Kato K. Lewis X-carrying N-glycans regulate the proliferation of mouse embryonic neural stem cells via the Notch signaling pathway. *J Biol Chem*. 2012; 287(29):24356–24364. M112.365643 [pii]. 10.1074/jbc.M112.365643 [PubMed: 22645129]
33. Nakatani Y, Yanagisawa M, Suzuki Y, Yu RK. Characterization of GD3 ganglioside as a novel biomarker of mouse neural stem cells. *Glycobiology*. 2010; 20(1):78–86. cwp149 [pii]. 10.1093/glycob/cwp149 [PubMed: 19776077]
34. Kanemura Y, Mori H, Kobayashi S, Islam O, Kodama E, Yamamoto A, Nakanishi Y, Arita N, Yamasaki M, Okano H, Hara M, Miyake J. Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity. *J Neurosci Res*. 2002; 69 (6):869–879.10.1002/jnr.10377 [PubMed: 12205680]
35. Yanagisawa M, Yu RK. O-linked beta-N-acetylglucosaminylation in mouse embryonic neural precursor cells. *J Neurosci Res*. 2009; 87 (16):3535–3545.10.1002/jnr.22170 [PubMed: 19598243]
36. Chen Y, Dong C. Abeta40 promotes neuronal cell fate in neural progenitor cells. *Cell Death Differ*. 2009; 16(3):386–394. cdd200894 [pii]. 10.1038/cdd.2008.94 [PubMed: 18566600]
37. Heo C, Chang KA, Choi HS, Kim HS, Kim S, Liew H, Kim JA, Yu E, Ma J, Suh YH. Effects of the monomeric, oligomeric, and fibrillar Abeta42 peptides on the proliferation and differentiation of adult neural stem cells from subventricular zone. *J Neurochem*. 2007; 102 (2):493–500. JNC4499 [pii]. 10.1111/j.1471-4159.2007.04499.x [PubMed: 17403034]
38. Lopez-Toledano MA, Shelanski ML. Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. *J Neurosci*. 2004; 24(23):5439–5444. 24/23/5439 [pii]. 10.1523/JNEUROSCI.0974-04.2004 [PubMed: 15190117]

39. Sotthibundhu A, Li QX, Thangnipon W, Coulson EJ. Abeta(1–42) stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor. *Neurobiol Aging*. 2009; 30(12):1975–1985. S0197-4580(08)00053-5 [pii]. 10.1016/j.neurobiolaging.2008.02.004 [PubMed: 18374455]
40. Yanagisawa M, Ariga T, Yu RK. Cytotoxic effects of G(M1) ganglioside and amyloid beta-peptide on mouse embryonic neural stem cells. *ASN Neuro*. 2010; 2 (1):e00029.10.1042/AN20090063 [PubMed: 20305711]
41. Yagi H, Yanagisawa M, Kato K, Yu RK. Lysosome-associated membrane protein 1 is a major SSEA-1-carrier protein in mouse neural stem cells. *Glycobiology*. 2010; 20(8):976–981. cwq054 [pii]. 10.1093/glycob/cwq054 [PubMed: 20360060]
42. Sansom SN, Griffiths DS, Faedo A, Kleinjan DJ, Ruan Y, Smith J, van Heyningen V, Rubenstein JL, Livesey FJ. The level of the transcription factor Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. *PLoS Genet*. 2009; 5 (6):e1000511.10.1371/journal.pgen.1000511 [PubMed: 19521500]
43. Shimoda Y, Tajima Y, Osanai T, Katsume A, Kohara M, Kudo T, Narimatsu H, Takashima N, Ishii Y, Nakamura S, Osumi N, Sanai Y. Pax6 controls the expression of Lewis x epitope in the embryonic forebrain by regulating alpha 1,3-fucosyltransferase IX expression. *J Biol Chem*. 2002; 277(3):2033–2039. M108495200 [pii]. 10.1074/jbc.M108495200 [PubMed: 11675393]
44. Imai T, Tokunaga A, Yoshida T, Hashimoto M, Mikoshiba K, Weinmaster G, Nakafuku M, Okano H. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. *Mol Cell Biol*. 2001; 21 (12):3888–3900.10.1128/MCB.21.12.3888-3900.2001 [PubMed: 11359897]
45. Okano H, Kawahara H, Toriya M, Nakao K, Shibata S, Imai T. Function of RNA-binding protein Musashi-1 in stem cells. *Exp Cell Res*. 2005; 306 (2):349–356. S0014-4827(05)00090-X [pii]. 10.1016/j.yexcr.2005.02.021 [PubMed: 15925591]
46. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature*. 1999; 399 (6738 Suppl):A23–31. [PubMed: 10392577]
47. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. *J Biol Chem*. 1996; 271 (34):20631–20635. [PubMed: 8702810]
48. Yan Y, Wang C. Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. *J Mol Biol*. 2006; 364 (5):853–862. S0022-2836(06)01255-1 [pii]. 10.1016/j.jmb.2006.09.046 [PubMed: 17046788]
49. Yang M, Teplow DB. Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. *J Mol Biol*. 2008; 384(2):450–464. S0022-2836(08)01164-9 [pii]. 10.1016/j.jmb.2008.09.039 [PubMed: 18835397]
50. Kaminsky YG, Marlatt MW, Smith MA, Kosenko EA. Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). *Exp Neurol*. 2010; 221(1):26–37. S0014-4886(09)00378-1 [pii]. 10.1016/j.expneurol.2009.09.005 [PubMed: 19751725]
51. Lau TL, Ambroggio EE, Tew DJ, Cappai R, Masters CL, Fidelio GD, Barnham KJ, Separovic F. Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. *J Mol Biol*. 2006; 356 (3):759–770. S0022-2836(05)01558-5 [pii]. 10.1016/j.jmb.2005.11.091 [PubMed: 16403524]
52. Lau TL, Gehman JD, Wade JD, Perez K, Masters CL, Barnham KJ, Separovic F. Membrane interactions and the effect of metal ions of the amyloidogenic fragment Abeta(25-35) in comparison to Abeta(1-42). *Biochim Biophys Acta*. 2007; 1768 (10):2400–2408. S0005-2736(07)00166-6 [pii]. 10.1016/j.bbamem.2007.05.004 [PubMed: 17574205]
53. Mattson MP, Begley JG, Mark RJ, Furukawa K. Abeta25-35 induces rapid lysis of red blood cells: contrast with Abeta1-42 and examination of underlying mechanisms. *Brain Res*. 1997; 771(1): 147–153. S0006-8993(97)00824-X [pii]. [PubMed: 9383018]
54. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35). *J Am Chem Soc*. 2001; 123(24):5625–5631. ja010452r [pii]. [PubMed: 11403592]

55. Miller BL, Williams TD, Schoneich C. Mechanism of sulfoxide formation through reaction of sulfur radical cation complexes with superoxide or hydroxide ion in oxygenated aqueous solution. *J Am Chem Soc.* 1996; 118 (45):11014–11025.10.1021/Ja962032l
56. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. *J Neurochem.* 1995; 64 (1):253–265. [PubMed: 7798921]
57. Varadarajan S, Yatin S, Kanski J, Jahanshahi F, Butterfield DA. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. *Brain Res Bull.* 1999; 50(2):133–141. S0361-9230(99)00093-3 [pii]. [PubMed: 10535332]
58. Yu RK, Ando S. Structures of some new complex gangliosides of fish brain. *Adv Exp Med Biol.* 1980; 125:33–45. [PubMed: 7361620]
59. Ando S, Yu RK. Isolation and characterization of two isomers of brain tetrasialogangliosides. *J Biol Chem.* 1979; 254 (23):12224–12229. [PubMed: 500707]
60. Comelli EM, Amado M, Lustig SR, Paulson JC. Identification and expression of Neu4, a novel murine sialidase. *Gene.* 2003; 321:155–161. S037811190300862X [pii]. [PubMed: 14637003]
61. Shiozaki K, Koseki K, Yamaguchi K, Shiozaki M, Narimatsu H, Miyagi T. Developmental change of sialidase neu4 expression in murine brain and its involvement in the regulation of neuronal cell differentiation. *J Biol Chem.* 2009; 284(32):21157–21164. M109.012708 [pii]. 10.1074/jbc.M109.012708 [PubMed: 19506080]
62. Tringali C, Cirillo F, Lamorte G, Papini N, Anastasia L, Lupo B, Silvestri I, Tettamanti G, Venerando B. NEU4L sialidase overexpression promotes beta-catenin signaling in neuroblastoma cells, enhancing stem-like malignant cell growth. *Int J Cancer.* 2012; 131 (8):1768–1778.10.1002/ijc.27450 [PubMed: 22287118]
63. Solter D, Knowles BB. Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). *Proc Natl Acad Sci U S A.* 1978; 75 (11):5565–5569. [PubMed: 281705]
64. Gooi HC, Feizi T, Kapadia A, Knowles BB, Solter D, Evans MJ. Stage-specific embryonic antigen involves alpha 1 goes to 3 fucosylated type 2 blood group chains. *Nature.* 1981; 292 (5819):156–158. [PubMed: 6165896]

Fig. 1. Effects of soluble Aβs (Aβ1-40 or Aβ1-42) on mouse NSCs in culture

a. Primary structures of Aβ peptides. **b.** NSCs were cultured for 3 days with or without Aβs. The number of NSCs in the monolayer culture in the presence of soluble Aβs (10 μM) was estimated by the WST-8 assay. The y-axis represents relative absorbance (Abs.), which represents the percentage of absorbance against vehicle treatment. Each bar represents mean ± SD of 8 independent experiments (n = 8). Comparison was made between vehicle versus each treatment. **p*<0.05.

Fig. 2. Structures and metabolic pathways of gangliosides

The nomenclature for gangliosides and the components are based on those of Svennerholm (1981) and IUPAC-IUBMB Joint Commission on Biochemical Nomenclature (1997). β -gal, lysosomal acid β -galactosidase; GalNAc-T, N-acetylgalactosaminyltransferase I (GA2/GM2/GD2/GT2-synthase); GalT-I, galactosyltransferase I (lactosylceramide synthase); GalT-II, galactosyltransferase II (GA1/GM1/GD1b/GT1c-synthase); GLCC, glucosylceramidase; GlcT, glucosyl transferase (glucosylceramide synthase); GM2A, GM2 activator protein; HEX, β -N-acetylhexosaminidase; ST-I, sialyltransferase I (GM3-synthase); ST-II, sialyltransferase II (GD3-synthase); ST-III, sialyltransferase III (GT3-synthase); ST-IV; sialyltransferase IV (GM1b/GD1a/GT1b/GQ1c-synthase); ST-V, sialyltransferase V (GD1c/GT1a/GQ1b/GP1c-synthase); ST-VII, sialyltransferase VII (GD1a α /GT1a α /GQ1b α /GP1c α -synthase).

Fig. 3. Aβ treatment alters glycosyltransferases and glycosidases expression in NSCs
 NSCs were cultured for 3 days with 10 μM of Aβ1-40 or Aβ1-42, or without Aβs. RT-PCR analyses were performed using specific primer sets. The enzymes for ganglioside metabolism are shown in Fig.1. Neu1, lysosomal sialidase; Neu3, plasma membrane sialidase; Neu4, mitochondrial sialidase; FUT9, α1-3 fucosyltransferase IX. G3PDH was used as a control. RT-PCR products were resolved on agarose gels and the intensity was quantified with normalization against G3PDH mRNA. The normalized value from control (vehicle) is defined as 1.0. Each bar represents mean ± SD of 3 independent experiments (n

= 3). * ($p < 0.05$) indicate the level of significance in two tailed t-tests of differences between vehicle versus each treatment.

Fig. 4. Expressions of neural cell lineage-associated markers

NSCs were cultured for 3 days with 10 μ M of A β 1-40 or A β 1-42, or without A β s. **a** RT-PCR analyses were performed for Nestin, MAP2, GFAP, Pax6 and Musashi-1. RT-PCR products were resolved on agarose gels and intensity was quantified with normalization against G3PDH mRNA. The normalized value from control (vehicle) is defined as 1.0. **b** Western blot of NSCs treated with A β s, and immunostained using anti-Notch1 intracellular domain (NICD), and anti-actin antibodies. Values were normalized by setting the NICD/Actin protein ratio for control (vehicle) in each treatment. Each bar represents mean $\pm$ SD of 3

independent experiments ($n = 3$). * ($p < 0.05$) indicate the level of significance in two tailed t-tests of differences between vehicle versus each treatment.

Table 1

Primer sequences used in this study

Abbreviation	Enzyme name	Sequence of primer
GlcT	GlcCer-synthase; Ceramide glucosyltransferase	5'-TGCATTTCATGTCCATCATCTAC-3' 5'-GTCATCTGATTACCATGTGACAG-3'
GalT-I	LacCer-synthase; UDP-Gal, GlcCer β 1-4 galactosyltransferase	5'-TCTACTTCATCTATGTGGCTCC-3' 5'-AGAAGAGCTGATGGACTTCATC-3'
ST-I (ST3Gal-V)	GM3-synthase; CMP-NeuAc, LacCer α 2-3 sialyltransferase	5'-TTTGGAGTCTGGCTCCTGTAC-3' 5'-CTCTCAAGTGTTCAGGAAAGTC-3'
ST-II (ST8Sia-I)	GD3-synthase; CMP-NeuAc, GM3 α 2-8 sialyltransferase	5'-ATGCTAGCTCGGAAATCCCG-3' 5'-CAGGGTCACAGCAGTCTTCC-3'
ST-III (ST8Sia-III)	GT3-synthase; CMP-NeuAc, GD3 α 2-8 sialyltransferase	5'-TCTTCAACCTCCCAAGTACG-3' 5'-CTGACTCCCCTGTCAAGATTCC-3'
GalNAcT	GA2/GM2/GD2/GT2-synthase; UDP-GalNAc, LacCer/GM3/GD3/GT3 β 1-4 N-acetylgalactosaminyltransferase	5'-ATCAAGGAGCAAGTGGTGGAG-3' 5'-CTATCAGCAGCTGGTCAGCC-3'
GalT-II	GA1/GM1/GD1b/GT1c-synthase; UDP-Gal, GA2/ GM2/GD2/GT2 β 1-3 galactosaminyltransferase	5'-TTGATTTCTAACTCTCATGCCTG-3' 5'-TCTTTGTATCAGCTCTGACACC-3'
ST-IV (ST3Gal-II)	GM1b/GD1a/GT1b/GQ1c-synthase; CMP-NeuAc, GA1/GM1/GD1b/GT1c α 2-3 sialyltransferase	5'-CATGGGTACCTTGCCCTACC-3' 5'-CCAGGCACGATCTGGAACAG-3'
ST-V/III (ST8Sia-V)	GD1c/GT1a/GQ1b/GT3-synthase; CMP-NeuAc, GM1b/GD1a/GT1b/GD3 α 2-8 sialyltransferase	5'-AAGGAGATCAACAGCGCTGAC-3' 5'-TACTGCGGGTGGAAAGTAG-3'
ST-VII (ST6GalNAc-VI)	GD1a/GT1aa/GQ1ba/GP1ca-synthase; CMP-NeuAc, GM1b/GD1a/GT1b/GQ1c α 2-6 sialyltransferase	5'-GCGGTACGAGTGTGTGTGAT-3' 5'-AGCACACGGAATACACTGGAAT-3'
GLCC	Glucosylceramidase, Glucocerebrosidase	5'-CGGTATCTTGGGCATATGGTG-3' 5'-GAAGTTGGATAACTGGAAGTCG-3'
HEX α	b-N-acetylhexosaminidase a-subunit	5'-TTCCAGTTCGGGTACCATGTC-3' 5'-TTGTATGCCATGACATCCAGTG-3'
HEX β	b-N-acetylhexosaminidase b-subunit	5'-TACAAGAGACATCATGGCCCTG-3' 5'-ATCGTTTGGGTATAGACATGAG-3'
Neu1	Lysosomal sialidase	5'-AAGTTCATCGCCATGAGGAGG-3' 5'-TCGGGGTTGAAATCGTGATCG-3'
Neu3	Plasma membrane sialidase	5'-ACTGATGGAGGCCACATTACC-3' 5'-TGAAGTGGCATGGTGCCATG-3'
Neu4	Mitochondrial sialidase	5'-AGCACTCTGGTACCATCTTCC-3' 5'-AGAGGGCTTCGAGCATTACAG-3'
β -Gal	b-N-acetylhexosaminidase a-subunit	5'-TGATGTGGAGCATTTCATCCAG-3' 5'-GTGTGATATTGTTGCCTGTTCC-3'
GM2A	GM2 activator protein	5'-ATGAAGGAAAGGACCCTGCAG-3' 5'-GAGGCAGCAATCTTGATGCAG-3'
FUT9	fucosyltransferase-IX	5'-TTCGCCCATTCTAATCGTC-3' 5'-TTGTGCTCACCCTCAAGAAG-3'
Nestin		5'-ATGGTGGAATGCAAGAAAGC-3' 5'-ATACCCAGCATGAAGGCATC-3'
MAP2		5'-CCTCAGCTGACAGAGAAACAG-3' 5'-CTTGGTTCTGTGCTCTGTTTT C-3'
GFAP		5'-ATCGAGATCGCCACCTACAG-3' 5'-CTCACATCACCACGTCTTTG-3'
Pax6		5'-CTGTACCAACGATAACATACCC-3' 5'-AGGAGTGTGTGCTGGCCTGTC-3'
Musashi-1		5'-AGCCATGTACGTAGCCATCC-3' 5'-TCTCAGCTGTGGTGGTGAG-3'
G3PDH	Glyceraldehyde-3-phosphate dehydrogenase	5'-ACCACAGTCCATGCCATCAC-3' 5'-TCCACCACCCTGTTGCTGTA-3'